Stockreport

Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea

Sol-Gel Technologies Ltd. - Ordinary Shares  (SLGL) 
Last sol-gel technologies ltd. - ordinary shares earnings: 11/13 07:05 am Check Earnings Report
PDF All primary and secondary endpoints achieved in both Phase 3 clinical trialsRapid efficacy demonstrated, with statistical significance reached as early as Week 2 compare [Read more]